Fundraising FoxOvobiomanufacturing
1 known investors
Find your way into Ovobiomanufacturing
Sign up to see every warm intro you have to Ovobiomanufacturing
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ovobiomanufacturing team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OVO Biomanufacturing offers a cloud-based software platform that helps viral vaccine manufacturers manage and reduce defective interfering particles (DIPs) to improve production yields. Using Next Generation Sequencing data, the platform guides producers to optimise DIP populations when creating working seed stocks for live attenuated and inactivated viral vaccines, with an initial focus on the influenza vaccine market.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- OVO BIOMANUFACTURING LTD
- Company number
- 12371825
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 19 Dec 2019
- Registered office
- Friars House, Manor House Drive, Coventry, CV1 2TE
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 18 Dec 2025 · next due 1 Jan 2027
Current officers · 2
- William Oliver Collier — director, appointed 19 Dec 2019
- Phillip Spencer Gould — director, appointed 19 Dec 2019
Source: Companies House public register · retrieved 20 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Ovobiomanufacturing do?
- OVO Biomanufacturing offers a cloud-based software platform that helps viral vaccine manufacturers manage and reduce defective interfering particles (DIPs) to improve production yields. Using Next Generation Sequencing data, the platform guides producers to optimise DIP populations when creating working seed stocks for live attenuated and inactivated viral vaccines, with an initial focus on the influenza vaccine market.
- Who are Ovobiomanufacturing's investors?
- Ovobiomanufacturing's investors include Oxford Technology Management.